A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

Description:

The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Sponsor:

Clarity Pharmaceuticals

Contacts:

Clarity Pharmaceuticals (Clarity Clinical)

clinicaltrials@claritypharmaceuticals.com

+61 0 2 9209 4037

Government Study Link:

NCT04868604 - Click here to see study on

ClinicalTrials.gov

Inclusion

•≥1 metastatic lesion that is present at screening CT, MRI, or bone scan imaging ≤28 days prior to enrolment
•Histological, pathological, and/or cytological confirmation of Prostate cancer (PCa)
•Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L)
•Have progressive metastatic castration-resistant prostate cancer (mCRPC) despite prior androgen deprivation therapy
•Eastern Cooperative Oncology Group performance status of 0 to 2

Exclusion

•Spinal metastasis with symptomatic cord compression, or clinical or radiologic indicative findings
•Prior history of leukemia or Myelodysplastic Syndrome
•Symptomatic Brain metastasis
•Histologic diagnosis of small cell or neuroendocrine prostate cancer

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States 🇺🇸

XCancer - Omaha

17607 Gold Plaza, Omaha, Nebraska 68130, United States